Preliminary study to identify the predictive factors for the response to methotrexate therapy in patients with rheumatoid arthritis

Sachie Inoue, Masayuki Hashiguchi, Kenji Takagi, Shinichi Kawai, Mayumi Mochizuki

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

To identify the major factors predicting the response to Methotrexate (MTX) therapy in rheumatoid arthritis (RA) patients, we evaluated the relationship between the response to MTX and factors such as the concentration of MTX-polyglutamates (MTX-PGs) in erythrocytes (RBCs), genotypes of thymidylate synthase (TYMS) 5′-UTR (2R/3R) and 3′-UTR (-6/+6), 5,10-methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C, and other patient-related factors. Thirty-six Japanese RA patients were enrolled in this cohort study. The concentrations of MTX-PGs in RBCs were measured, and polymorphisms were determined using PCR-RFLP method. As an indicator of the accumulated capacity of MTX-PGs in the RBCs of each patient, the MTX dose/MTX-PGs (AC-MPG, l/week) was calculated. The response to MTX therapy was assessed using the MTX dose for a ≥50% decrease in CRP level (MTX dose for 50% CRP, mg/week), and the relationships between MTX dose for 50% CRP and various other factors were evaluated using multiple linear regression analysis. The MTX dose was 6.9±0.3 mg/week and the MTX-PGs concentration in RBCs was 97.3±8.1 nmol/l (n=36, blood samples=95, mean±S.D.). The range of MTX dose for 50% CRP was 2.0-13.0 mg/ week. Most individual AC-MPG levels showed no change during the evaluation period (coefficient of variation=5.9%). Based on the results of multiple linear regression analysis, AC-MPG, TYMS 3′-UTR (-6/+6), and ESR at the start of MTX therapy were associated with the MTX dose for 50%CRP. AC-MPG, TYMS 3′-UTR (-6/+6), and ESR might be the major predictive factors for the response to MTX therapy in Japanese RA patients.

Original languageEnglish
Pages (from-to)843-849
Number of pages7
JournalYakugaku Zasshi
Volume129
Issue number7
DOIs
Publication statusPublished - 2009 Jul

Fingerprint

Methotrexate
Rheumatoid Arthritis
Therapeutics
Thymidylate Synthase
3' Untranslated Regions
Linear Models
Regression Analysis
Methylenetetrahydrofolate Reductase (NADPH2)
5' Untranslated Regions
Restriction Fragment Length Polymorphisms
Cohort Studies

Keywords

  • Clinical trial
  • Methotrexate
  • Methotrexate-polyglutamates
  • Polymorphism
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Preliminary study to identify the predictive factors for the response to methotrexate therapy in patients with rheumatoid arthritis. / Inoue, Sachie; Hashiguchi, Masayuki; Takagi, Kenji; Kawai, Shinichi; Mochizuki, Mayumi.

In: Yakugaku Zasshi, Vol. 129, No. 7, 07.2009, p. 843-849.

Research output: Contribution to journalArticle

Inoue, Sachie ; Hashiguchi, Masayuki ; Takagi, Kenji ; Kawai, Shinichi ; Mochizuki, Mayumi. / Preliminary study to identify the predictive factors for the response to methotrexate therapy in patients with rheumatoid arthritis. In: Yakugaku Zasshi. 2009 ; Vol. 129, No. 7. pp. 843-849.
@article{2899a6d6cacf40d68a29b2ba27aa4cf1,
title = "Preliminary study to identify the predictive factors for the response to methotrexate therapy in patients with rheumatoid arthritis",
abstract = "To identify the major factors predicting the response to Methotrexate (MTX) therapy in rheumatoid arthritis (RA) patients, we evaluated the relationship between the response to MTX and factors such as the concentration of MTX-polyglutamates (MTX-PGs) in erythrocytes (RBCs), genotypes of thymidylate synthase (TYMS) 5′-UTR (2R/3R) and 3′-UTR (-6/+6), 5,10-methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C, and other patient-related factors. Thirty-six Japanese RA patients were enrolled in this cohort study. The concentrations of MTX-PGs in RBCs were measured, and polymorphisms were determined using PCR-RFLP method. As an indicator of the accumulated capacity of MTX-PGs in the RBCs of each patient, the MTX dose/MTX-PGs (AC-MPG, l/week) was calculated. The response to MTX therapy was assessed using the MTX dose for a ≥50{\%} decrease in CRP level (MTX dose for 50{\%} CRP, mg/week), and the relationships between MTX dose for 50{\%} CRP and various other factors were evaluated using multiple linear regression analysis. The MTX dose was 6.9±0.3 mg/week and the MTX-PGs concentration in RBCs was 97.3±8.1 nmol/l (n=36, blood samples=95, mean±S.D.). The range of MTX dose for 50{\%} CRP was 2.0-13.0 mg/ week. Most individual AC-MPG levels showed no change during the evaluation period (coefficient of variation=5.9{\%}). Based on the results of multiple linear regression analysis, AC-MPG, TYMS 3′-UTR (-6/+6), and ESR at the start of MTX therapy were associated with the MTX dose for 50{\%}CRP. AC-MPG, TYMS 3′-UTR (-6/+6), and ESR might be the major predictive factors for the response to MTX therapy in Japanese RA patients.",
keywords = "Clinical trial, Methotrexate, Methotrexate-polyglutamates, Polymorphism, Rheumatoid arthritis",
author = "Sachie Inoue and Masayuki Hashiguchi and Kenji Takagi and Shinichi Kawai and Mayumi Mochizuki",
year = "2009",
month = "7",
doi = "10.1248/yakushi.129.843",
language = "English",
volume = "129",
pages = "843--849",
journal = "Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan",
issn = "0031-6903",
publisher = "Pharmaceutical Society of Japan",
number = "7",

}

TY - JOUR

T1 - Preliminary study to identify the predictive factors for the response to methotrexate therapy in patients with rheumatoid arthritis

AU - Inoue, Sachie

AU - Hashiguchi, Masayuki

AU - Takagi, Kenji

AU - Kawai, Shinichi

AU - Mochizuki, Mayumi

PY - 2009/7

Y1 - 2009/7

N2 - To identify the major factors predicting the response to Methotrexate (MTX) therapy in rheumatoid arthritis (RA) patients, we evaluated the relationship between the response to MTX and factors such as the concentration of MTX-polyglutamates (MTX-PGs) in erythrocytes (RBCs), genotypes of thymidylate synthase (TYMS) 5′-UTR (2R/3R) and 3′-UTR (-6/+6), 5,10-methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C, and other patient-related factors. Thirty-six Japanese RA patients were enrolled in this cohort study. The concentrations of MTX-PGs in RBCs were measured, and polymorphisms were determined using PCR-RFLP method. As an indicator of the accumulated capacity of MTX-PGs in the RBCs of each patient, the MTX dose/MTX-PGs (AC-MPG, l/week) was calculated. The response to MTX therapy was assessed using the MTX dose for a ≥50% decrease in CRP level (MTX dose for 50% CRP, mg/week), and the relationships between MTX dose for 50% CRP and various other factors were evaluated using multiple linear regression analysis. The MTX dose was 6.9±0.3 mg/week and the MTX-PGs concentration in RBCs was 97.3±8.1 nmol/l (n=36, blood samples=95, mean±S.D.). The range of MTX dose for 50% CRP was 2.0-13.0 mg/ week. Most individual AC-MPG levels showed no change during the evaluation period (coefficient of variation=5.9%). Based on the results of multiple linear regression analysis, AC-MPG, TYMS 3′-UTR (-6/+6), and ESR at the start of MTX therapy were associated with the MTX dose for 50%CRP. AC-MPG, TYMS 3′-UTR (-6/+6), and ESR might be the major predictive factors for the response to MTX therapy in Japanese RA patients.

AB - To identify the major factors predicting the response to Methotrexate (MTX) therapy in rheumatoid arthritis (RA) patients, we evaluated the relationship between the response to MTX and factors such as the concentration of MTX-polyglutamates (MTX-PGs) in erythrocytes (RBCs), genotypes of thymidylate synthase (TYMS) 5′-UTR (2R/3R) and 3′-UTR (-6/+6), 5,10-methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C, and other patient-related factors. Thirty-six Japanese RA patients were enrolled in this cohort study. The concentrations of MTX-PGs in RBCs were measured, and polymorphisms were determined using PCR-RFLP method. As an indicator of the accumulated capacity of MTX-PGs in the RBCs of each patient, the MTX dose/MTX-PGs (AC-MPG, l/week) was calculated. The response to MTX therapy was assessed using the MTX dose for a ≥50% decrease in CRP level (MTX dose for 50% CRP, mg/week), and the relationships between MTX dose for 50% CRP and various other factors were evaluated using multiple linear regression analysis. The MTX dose was 6.9±0.3 mg/week and the MTX-PGs concentration in RBCs was 97.3±8.1 nmol/l (n=36, blood samples=95, mean±S.D.). The range of MTX dose for 50% CRP was 2.0-13.0 mg/ week. Most individual AC-MPG levels showed no change during the evaluation period (coefficient of variation=5.9%). Based on the results of multiple linear regression analysis, AC-MPG, TYMS 3′-UTR (-6/+6), and ESR at the start of MTX therapy were associated with the MTX dose for 50%CRP. AC-MPG, TYMS 3′-UTR (-6/+6), and ESR might be the major predictive factors for the response to MTX therapy in Japanese RA patients.

KW - Clinical trial

KW - Methotrexate

KW - Methotrexate-polyglutamates

KW - Polymorphism

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=67650073102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650073102&partnerID=8YFLogxK

U2 - 10.1248/yakushi.129.843

DO - 10.1248/yakushi.129.843

M3 - Article

C2 - 19571519

AN - SCOPUS:67650073102

VL - 129

SP - 843

EP - 849

JO - Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan

JF - Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan

SN - 0031-6903

IS - 7

ER -